SCHEMBL1713746

SCHEMBL1713746

CCCCC(C)OC(=O)CCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.49
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
LMNA P02545 2/20 0.47
EPHX2 P34913 1/20 0.46
AKR1B1 P15121 1/20 0.43
GPR84 Q9NQS5 7/20 0.42
PPARG P37231 6/20 0.42
PPARD Q03181 6/20 0.42
PPARA Q07869 6/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
PTPN1 P18031 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28562346 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL29061012 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL27296733 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL28788315 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL27311668 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL29608607 0.93 FAAH (0.58) FAAHCNR1CNR2LMNAGPR84
SCHEMBL1713745 0.92 FAAH (0.54) FAAHCNR1CNR2LMNAEPHX2
SCHEMBL28863965 0.91 LMNA (0.50) FAAHCNR1CNR2LMNAEPHX2
SCHEMBL10450191 0.91 LMNA (0.55) FAAHCNR1CNR2LMNAEPHX2
SCHEMBL11230135 0.89 LMNA (0.58) FAAHCNR1CNR2LMNAAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114901360-A Novel lipid nanoparticles for delivery of nucleic acids 库瑞瓦格股份公司 2022-08-12 CN disclosed
EP-3233889-B1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
CN-107257803-B Polymyxin antibacterial agents for the treatment of bacterial infections 上海盟科药业股份有限公司 2021-02-05 CN disclosed
EP-3233889-A2 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS Micurx Pharmaceuticals, Inc. (US) 2017-10-25 EP disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
EP-1765529-B1 PROCESS FOR STIMULATING PRODUCTION OF HYDROGEN FROM PETROLEUM IN SUBTERRANEAN FORMATIONS UNIV NEWCASTLE (GB) 2011-07-20 EP disclosed
EP-1776198-B1 PROCESS FOR STIMULATING PRODUCTION OF METHANE FROM PETROLEUM IN SUBTERRANEAN FORMATIONS UNIV NEWCASTLE (GB) 2011-07-20 EP disclosed
US-20100035309-A1 ANALYSIS AND ENHANCEMENT OF METABOLIC PATHWAYS FOR METHANOGENESIS LUCA TECHNOLOGIES, INC. (US) 2010-02-11 US disclosed
US-20070298479-A1 Process For Stimulating Production Of Hydrogen From Petroleum In Subterranean Formations NORSK HYDRO ASA (NO) 2007-12-27 US disclosed
US-7304032-B2 CD-10 activated prodrug compounds MEDAREX, INC. (US) 2007-12-04 US disclosed
US-20070251146-A1 Process for Stimulating Production of Methane From Petroleum in Subterranean Formations THE UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2007-11-01 US disclosed
EP-1776198-A1 PROCESS FOR STIMULATING PRODUCTION OF METHANE FROM PETROLEUM IN SUBTERRANEAN FORMATIONS University of Newcastle upon Tyne (GB) 2007-04-25 EP disclosed
EP-1765529-A1 PROCESS FOR STIMULATING PRODUCTION OF HYDROGEN FROM PETROLEUM IN SUBTERRANEAN FORMATIONS University of Newcastle upon Tyne (GB) 2007-03-28 EP disclosed
WO-2005115648-A1 PROCESS FOR STIMULATING PRODUCTION OF HYDROGEN FROM PETROLEUM IN SUBTERRANEAN FORMATIONS UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2005-12-08 WO disclosed
WO-2005115649-A1 PROCESS FOR STIMULATING PRODUCTION OF METHANE FROM PETROLEUM IN SUBTERRANEAN FORMATIONS UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS VIP, AQP1, PEF1 FAAH 3284/4885CNR1 4198/4885CNR2 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.